JP4817498B2 - チアゾリン酸誘導体 - Google Patents

チアゾリン酸誘導体 Download PDF

Info

Publication number
JP4817498B2
JP4817498B2 JP2000567521A JP2000567521A JP4817498B2 JP 4817498 B2 JP4817498 B2 JP 4817498B2 JP 2000567521 A JP2000567521 A JP 2000567521A JP 2000567521 A JP2000567521 A JP 2000567521A JP 4817498 B2 JP4817498 B2 JP 4817498B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
salt
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000567521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523500A5 (https=
JP2002523500A (ja
Inventor
バーゲロン，レイモンド，ジェイ．，ジュニア
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2002523500A publication Critical patent/JP2002523500A/ja
Publication of JP2002523500A5 publication Critical patent/JP2002523500A5/ja
Application granted granted Critical
Publication of JP4817498B2 publication Critical patent/JP4817498B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Game Rules And Presentations Of Slot Machines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
JP2000567521A 1998-08-31 1999-08-31 チアゾリン酸誘導体 Expired - Fee Related JP4817498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/144,103 US6083966A (en) 1998-08-31 1998-08-31 Thiazoline acid derivatives
US09/144,103 1998-08-31
PCT/US1999/019691 WO2000012493A1 (en) 1998-08-31 1999-08-31 Thiazoline acid derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011095879A Division JP5520875B2 (ja) 1998-08-31 2011-04-22 チアゾリン酸誘導体

Publications (3)

Publication Number Publication Date
JP2002523500A JP2002523500A (ja) 2002-07-30
JP2002523500A5 JP2002523500A5 (https=) 2011-07-21
JP4817498B2 true JP4817498B2 (ja) 2011-11-16

Family

ID=22507049

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000567521A Expired - Fee Related JP4817498B2 (ja) 1998-08-31 1999-08-31 チアゾリン酸誘導体
JP2011095879A Expired - Fee Related JP5520875B2 (ja) 1998-08-31 2011-04-22 チアゾリン酸誘導体
JP2013257270A Pending JP2014065730A (ja) 1998-08-31 2013-12-12 チアゾリン酸誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011095879A Expired - Fee Related JP5520875B2 (ja) 1998-08-31 2011-04-22 チアゾリン酸誘導体
JP2013257270A Pending JP2014065730A (ja) 1998-08-31 2013-12-12 チアゾリン酸誘導体

Country Status (23)

Country Link
US (9) US6083966A (https=)
EP (1) EP1109795B1 (https=)
JP (3) JP4817498B2 (https=)
KR (1) KR20010074907A (https=)
CN (1) CN100455574C (https=)
AT (1) ATE317392T1 (https=)
AU (1) AU759851B2 (https=)
BR (1) BR9913441B1 (https=)
CA (1) CA2342210C (https=)
CZ (1) CZ2001711A3 (https=)
DE (1) DE69929807T2 (https=)
EA (1) EA200100261A1 (https=)
ES (1) ES2260933T3 (https=)
HU (1) HUP0103165A3 (https=)
IL (2) IL141611A0 (https=)
NO (1) NO321028B1 (https=)
NZ (1) NZ509899A (https=)
PL (1) PL346852A1 (https=)
PT (1) PT1109795E (https=)
TR (1) TR200100541T2 (https=)
UA (1) UA57161C2 (https=)
WO (1) WO2000012493A1 (https=)
YU (1) YU21801A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014065730A (ja) * 1998-08-31 2014-04-17 Univ Of Florida Research Foundation Inc チアゾリン酸誘導体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488791A3 (en) * 1998-09-21 2005-04-06 University Of Florida Research Foundation, Inc. Antimalarial agents
CN1585639A (zh) * 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
WO2001028595A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
CA2427146A1 (en) * 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US7038073B2 (en) * 2002-05-15 2006-05-02 Genzyme Corporation Synthesis of 2-alkyl amino acids
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
JPWO2004031163A1 (ja) * 2002-10-01 2006-02-02 株式会社カネカ 光学活性α−置換システインまたはその塩の製造方法並びにその合成中間体及びその製造方法
US20040185028A1 (en) * 2003-03-19 2004-09-23 Zhenze Hu Antimicrobial compositions containing ethanolamine buffer and biguanide disinfectant
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP2007505044A (ja) * 2003-09-09 2007-03-08 ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド ポリアミン−金属キレーター接合体
WO2005055931A2 (en) * 2003-12-03 2005-06-23 University Of Medicine And Dentistry Of New Jersey Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
WO2005075475A1 (ja) * 2004-02-04 2005-08-18 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するナフチリジン誘導体
TR201910900T4 (tr) * 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
US7365371B2 (en) 2005-08-04 2008-04-29 Cree, Inc. Packages for semiconductor light emitting devices utilizing dispensed encapsulants
EP2101764A4 (en) * 2006-12-12 2010-02-17 Univ Florida ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
MY163516A (en) * 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
EP2566854A4 (en) 2010-05-04 2013-11-06 Shire Llc DESAZADESFERROTHIOCIN AND DEAZADESFERROTHIOCIN POLYETHER ANALOGS AS METAL CHELATORS
CN103562379A (zh) * 2011-05-19 2014-02-05 国立大学法人德岛大学 细胞分化诱导剂以及分化诱导方法
EP3620161A1 (en) 2011-12-16 2020-03-11 University of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
JP6353751B2 (ja) * 2013-09-25 2018-07-04 国立大学法人電気通信大学 新規複素環式化合物及びその塩、並びに、発光基質組成物
AU2014352780A1 (en) * 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274207A (en) 1966-09-20 Processes for preparing thiazole carboxylic acids
US3809754A (en) 1968-12-31 1974-05-07 Medial De Toledo & Cie Method of treating diseases of the mucous membrane using compounds of a thiazolidine carboxylic acid and pharmaceutical preparations thereof
US3882110A (en) 1969-06-11 1975-05-06 Roussel Uclaf Novel 2-alkyl-5-thiazole-carboxylic acid derivatives
IT1050117B (it) 1969-09-17 1981-03-10 Godo Shusei Kk Metodo per la sintesi dell acido aeruginoico
FR2062120A5 (https=) 1969-10-10 1971-06-25 Messier Fa
FR2141526B1 (https=) 1971-06-14 1975-05-30 Roussel Uclaf
DE2245560A1 (de) 1972-09-16 1974-03-21 Basf Ag Verfahren zur herstellung von 4alkoxycarbonyl-2-thiazolinen
AU528115B2 (en) 1978-04-08 1983-04-14 Santen Pharmaceutical Co. Ltd. Antihypertensive 4-thiazolidine/carboxylic acids
CS205217B1 (cs) 1979-04-05 1981-05-29 Zdenek Vitamvas Dozimetr ionizujícího záření
DE3002989A1 (de) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
ZA815129B (en) * 1980-07-28 1982-07-28 Ciba Geigy Ag Thiazoline derivatives and processes for their manufacture
DE3170401D1 (en) * 1980-07-28 1985-06-13 Ciba Geigy Ag Triazoline derivatives and processes for their preparation
JPS5772975A (en) 1980-10-24 1982-05-07 Kureha Chem Ind Co Ltd 2-substituted phenylthiazole derviative, and medicine for peptic ulcer containing said derivative as active component
US4367233A (en) 1981-10-02 1983-01-04 American Home Products Corporation Inhibitors of mammalian collagenase
DE3586683T2 (de) 1984-12-18 1993-04-08 Clark Pharma Dev Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln.
HU200177B (en) 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
EP0214933A3 (de) 1985-09-03 1989-05-24 Ciba-Geigy Ag Kombinationspräparate zur Behandlung von Malaria
EP0214101A3 (de) 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
DE3735757A1 (de) 1987-10-22 1989-05-03 Degussa Optisch aktive salze aus einem substituierten thiazolidin-4-carboxylat und 3-chlor-2-hydroxypropyltrimethylammonium, deren herstellung und verwendung
EP0325559B1 (de) 1988-01-20 1993-12-15 Ciba-Geigy Ag Verfahren zur Herstellung von Komplexverbindungen
US5182402A (en) 1988-11-07 1993-01-26 Imperial Chemical Industries Plc Herbicidal compositions
GB8826035D0 (en) 1988-11-07 1988-12-14 Ici Plc Herbicidal compositions
US5106992A (en) 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
NL9001955A (nl) 1990-09-05 1992-04-01 Cedona Pharm Bv Nieuwe thiazolidinederivaten.
US5393777A (en) 1990-11-15 1995-02-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Deferration using anguibactin siderophore
DK0934937T3 (da) 1990-11-30 2002-04-02 Otsuka Pharma Co Ltd Azolderivater som superoxidradikalinhibitor
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
FR2677021B1 (fr) 1991-05-31 1993-10-01 Upsa Laboratoires Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5840739A (en) * 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
WO1994011367A1 (en) * 1992-11-16 1994-05-26 University Of Florida Research Foundation Inc. 2-(pyrid-2'-yl)-2-thiazoline-4(s)-carboxylic acid derivatives
DE4301356A1 (de) 1993-01-20 1994-07-21 Basf Ag Verfahren zur Herstellung von 2-Alkyl-4-fluormethyl-thiazolcarbonsäure-alkylestern
FR2749583B1 (fr) 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US20020049316A1 (en) 1997-04-29 2002-04-25 Halbert Stacie Marie Protease inhibitors
US6373912B1 (en) * 1997-06-16 2002-04-16 Legerity, Inc. Phase-locked loop arrangement with fast lock mode
US6174070B1 (en) * 1998-03-02 2001-01-16 Elna Kabushiki Kaisha Portable lighting instrument having a light emitting diode assembly
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
US6147070A (en) 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US6159983A (en) 1998-09-18 2000-12-12 University Of Florida Method and composition for treatment of inflammatory bowel disease
CN1585639A (zh) * 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
DE19919336A1 (de) 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
JP2007505044A (ja) 2003-09-09 2007-03-08 ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド ポリアミン−金属キレーター接合体
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
WO2006055412A1 (en) 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
EP2101764A4 (en) * 2006-12-12 2010-02-17 Univ Florida ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014065730A (ja) * 1998-08-31 2014-04-17 Univ Of Florida Research Foundation Inc チアゾリン酸誘導体

Also Published As

Publication number Publication date
WO2000012493A9 (en) 2002-04-11
HK1035720A1 (en) 2003-04-24
US6083966A (en) 2000-07-04
JP5520875B2 (ja) 2014-06-11
CN1313856A (zh) 2001-09-19
US20030236417A1 (en) 2003-12-25
EP1109795A4 (en) 2002-01-16
CZ2001711A3 (cs) 2001-09-12
US7531563B2 (en) 2009-05-12
YU21801A (sh) 2005-07-19
US6525080B1 (en) 2003-02-25
US20050033057A1 (en) 2005-02-10
EP1109795A1 (en) 2001-06-27
WO2000012493A1 (en) 2000-03-09
CA2342210A1 (en) 2000-03-09
CA2342210C (en) 2009-03-10
HUP0103165A2 (hu) 2002-01-28
NO321028B1 (no) 2006-02-27
AU759851B2 (en) 2003-05-01
HUP0103165A3 (en) 2003-03-28
NZ509899A (en) 2003-12-19
ES2260933T3 (es) 2006-11-01
JP2002523500A (ja) 2002-07-30
IL141611A0 (en) 2002-03-10
NO20011003L (no) 2001-02-27
TR200100541T2 (tr) 2001-11-21
IL141611A (en) 2006-12-31
USRE39132E1 (en) 2006-06-13
BR9913441A (pt) 2001-10-23
US6521652B1 (en) 2003-02-18
PL346852A1 (en) 2002-03-11
KR20010074907A (ko) 2001-08-09
US20070238767A1 (en) 2007-10-11
NO20011003D0 (no) 2001-02-27
CN100455574C (zh) 2009-01-28
US7126004B2 (en) 2006-10-24
DE69929807D1 (de) 2006-04-20
US20100094016A1 (en) 2010-04-15
AU5789799A (en) 2000-03-21
DE69929807T2 (de) 2006-11-02
JP2014065730A (ja) 2014-04-17
EA200100261A1 (ru) 2001-10-22
BR9913441B1 (pt) 2013-10-29
EP1109795B1 (en) 2006-02-08
JP2011178797A (ja) 2011-09-15
US6559315B1 (en) 2003-05-06
US8008502B2 (en) 2011-08-30
ATE317392T1 (de) 2006-02-15
UA57161C2 (uk) 2003-06-16
PT1109795E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
JP5520875B2 (ja) チアゾリン酸誘導体
JP3800559B2 (ja) チアゾリン酸誘導体
NZ526880A (en) Antimalarial agents
HK1035720B (en) Thiazoline acid derivatives
MXPA01001968A (en) Thiazoline acid derivatives
EP1488791A2 (en) Antimalarial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101224

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110804

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110830

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees